Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mereo BioPharma Group Temettü

Temettü kriter kontrolleri 0/6

Mereo BioPharma Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.24
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MREO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MREO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Mereo BioPharma Group Piyasaya Karşı Temettü Getirisi

MREO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MREO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (MREO) (3 yıla kadar)	n/a

Önemli Temettü: MREO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MREO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MREO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MREO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Mereo BioPharma Group Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Less than half of directors are independent

Less than half of directors are independent

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo Biopharma Group plc Announces Board Changes

Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan

Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors

Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Astrazeneca Reportedly Considering Take over Offer for Mereo

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Rubric Capital Sends Letter to Mereo BioPharma

Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

Rubric Capital Discloses its Views on Mereo BioPharma

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors

The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease

Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Mereo BioPharma Group plc has completed a Follow-on Equity Offering in the amount of $100.05 million.

Mereo BioPharma Group plc, Annual General Meeting, Feb 01, 2021

Ultragenyx Pharmaceutical Inc. and Mereo Biopharma Group plc Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Mereo Biopharma Provides Update with Respect to the Cancellation of Admission of Its Ordinary Shares to Trading on Aim

Mereo Biopharma Group plc Announces the Appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, Effective December 7, 2020

Mereo BioPharma Group Plans Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

Mereo BioPharma Group plc Announces Changes to Board of Directors

Mereo Biopharma Group plc Receives U.S. Food and Drug Administration Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

Mereo BioPharma Group plc Announces Initiation of Placebo-Controlled Phase 1B/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin